What is the ark venture fund?

The Ark Venture Fund is a venture-style investment fund run by ARK Invest (Cathie Wood’s firm) designed to invest primarily in private, high-growth companies (and sometimes a mix of public “innovation” stocks). In plain terms: it’s ARK’s way to offer investors exposure to venture-backed companies that aren’t publicly traded yet—without those investors needing to join a traditional venture capital (VC) partnership.

What the Ark Venture Fund is (in startup terms)

Traditional VC funds are usually structured as limited partnerships: a small group of investors commit capital for ~10 years, the VC invests in startups, and returns come from acquisitions or IPOs. The Ark Venture Fund aims to package a similar idea—owning stakes in private companies—in a format that is easier for a wider set of investors to access.

Key concept: private-company exposure. Most people can’t buy shares in private startups. A venture fund can, by participating in funding rounds or buying shares from existing shareholders (called secondary transactions).

How it typically invests (primary vs. secondary)

When you hear that a fund invests in “private companies,” there are two common ways that happens:

• Primary investment: the fund invests directly into a new funding round (e.g., Series C/D). The company issues new shares and receives cash on its balance sheet.
• Secondary purchase: the fund buys existing shares from an employee, early investor, or another shareholder. The company usually does not receive that cash (it goes to the seller), though the company may need to approve the transfer.

For founders, this distinction matters because a primary investment extends runway (cash to the company), while a secondary transaction is more about liquidity for individuals and cap table (ownership table) management.

Stage focus: usually later-stage private companies

Funds like this often target later-stage private companies (think “pre-IPO” or “growth-stage”) because those companies are more likely to have measurable traction and clearer paths to liquidity. Early-stage investing (seed/Series A) is possible, but it’s harder to scale and riskier.

Why it exists: the “private markets are hard to access” problem

Over the last decade, many startups have stayed private longer. That means a lot of value creation can happen before an IPO. Investors who only buy public stocks may miss that earlier growth phase.

The Ark Venture Fund exists to bridge that gap by:

• Giving investors a vehicle to access private-company stakes.
• Letting ARK apply its “disruptive innovation” thesis to private markets.
• Potentially combining private holdings with public innovation equities to manage liquidity (details vary by fund design and disclosures).

What founders should know if ARK shows interest

If you’re a technical/medical/scientific founder, the important question isn’t “what’s the fund called?” It’s: what does this investor want, and what does it mean for my company?

1) They may care about narrative + category leadership

ARK is known for thematic investing (e.g., AI, genomics, robotics, energy storage). That can be a fit if your company clearly maps to a large “disruptive innovation” theme and you can articulate:

• Why now (timing inflection: regulation, compute, cost curves, reimbursement, etc.).
• Why you (unique data, IP, clinical evidence, distribution advantage).
• Why it becomes big (credible path to a large market and durable margins).

Business jargon decoded: category leadership means being one of the top few companies in a market segment, not just having a clever technology.

2) Expect diligence that looks different from a seed VC

Later-stage investors often focus on measurable traction and unit economics. Unit economics means the profitability of one “unit” of your business (one customer, one procedure, one device, one subscription). Even if you’re not profitable yet, they’ll want to see a plausible path.

Be ready to answer:

• Revenue quality (recurring vs. one-time; contracted vs. “hopeful”).
• Gross margin and what drives it (COGS, cloud costs, clinical ops, support).
• Customer acquisition cost (CAC) and payback period (how long to earn it back).
• Retention (do customers stick around?) and expansion (do they buy more?).

3) Secondary transactions can be a double-edged sword

Secondaries can help retain talent (employees can get some liquidity) and reduce pressure for an early exit. But they can also create misalignment if too much liquidity happens too early, or if the cap table becomes messy.

Founder-friendly rule of thumb: if you allow secondaries, tie them to clear milestones (e.g., after a priced round, with board approval, limited percentage of holdings). The right structure depends on your stage and governance.

4) Liquidity and valuation expectations matter

Private-company investing is illiquid: you can’t easily sell tomorrow. Funds that offer investors more frequent entry/exit features must manage liquidity carefully, which can influence what they buy and how they size positions.

As a founder, you should understand:

• Whether they want primary (new money into the company) or secondary (buying existing shares).
• How they think about valuation (what comparables or growth assumptions they use).
• What rights they request (information rights, pro-rata, board seat, etc.).

Business jargon decoded: pro-rata is the right to maintain ownership percentage in future rounds by investing again.

How it differs from “ARK ETFs” (and why people confuse them)

Many people know ARK through its public-market ETFs (exchange-traded funds) that hold publicly traded stocks. The Ark Venture Fund is different because it targets private companies (with possible public holdings depending on the fund’s mandate).

The confusion happens because both share the ARK brand and “innovation” thesis, but they operate in different market structures:

• ETFs: liquid public stocks; priced continuously by the market.
• Venture-style fund: illiquid private shares; valuations update less frequently and are based on funding rounds or appraisal methods.

What to do next

1. Clarify your goal: Are you raising primary capital, enabling employee liquidity (secondary), or both? Write it down before taking investor meetings.
2. Pressure-test your “why now + why you” story with a tight 10-slide deck and a 1-page memo. If you want feedback, run it through /roast.
3. Get your metrics in order: revenue quality, gross margin drivers, CAC/payback, retention. If you’re pre-revenue (common in deep tech/biotech), define milestone-based traction (pilots, LOIs, clinical endpoints) and the cost to reach each milestone.
4. Map your cap table scenarios (including secondaries) so you know the dilution and control implications. Use /finances to model outcomes.
5. Benchmark investor fit by studying comparable companies and who funded them. Start with /Competitor_study.